8-K - Monopar Therapeutics Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

. Regulation FD Disclosure On March 2, 2026, Monopar Therapeutics Inc. (“Monopar”) issued a press release announcing the appointment of Susan Rodriguez as Chief

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated March 2, 2026. 104 Cover Page Interactive Data File - the cove

Exhibits Only

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1